Security
Veraxa Biotech AG Ordinary Shares · VRXA
VRXANASDAQCommon stockCurrentCIK 2079109Updated Oct 30, 2026
Name history
Veraxa Biotech Holding AG · through Aug 13, 2026
VRXA price & chart
Loading TradingView…
NASDAQ:VRXA on TradingView ↗About the company
VERAXA is building a premier engine for the discovery and development of next-generation antibody-based cancer therapeutics, powered by a suite of transformative technologies and guided by rigorous quality-by-design principles. The Company is rapidly advancing its pipeline of conditionally active T cell engagers (BiTAC-TCEs), bispecific antibody-drug conjugates (bsADCs), and proprietary BiTAC formats into clinical development. Uniquely, VERAXA has implemented FDA-aligned New Approach Methodologies across all preclinical programs, enabling faster clinical advancement while reducing reliance on animal testing. Founded on scientific breakthroughs from the European Molecular Biology Laboratory (EMBL), a world-renowned institution for pioneering life science research, VERAXA combines innovation with responsible research practices.
In the news
VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Advance BiTAC® Technology Platforms and Portfolio ↗
Recent filings
Show 5 more recent filings
Offerings
Registration 333-297907
Registration 333-297908
Filing attachments
veraxabiotechag_ex99-1.htm · 6-K · 2026-10-15
Exhibit 99.1 Press Release VERAXA Biotech Presents in vivo Proof-of-Concept Data for BiTAC®-ADC Technology at World ADC Congress In vivo data confirm activation of prodrug payload inside tumor cells following systemic administration of BiTAC-ADC molecules leading to potent anti-tumor activity ZURICH, SWITZERLAND - October 13, 2026 - VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today presented first in vivo proof-of-concept data and addit…
Read attachment ↗veraxabiotechag_ex99-1.htm · 6-K · 2026-09-04
Exhibit 99.1 Press Release VERAXA Biotech Appoints Raju Willener as Chief Financial Officer Mr. Willener brings more than three decades of global capital markets and corporate finance experience to support advancement of the Company’s pipeline of potential best-in-class therapies led by its BiTAC ® platform ZURICH, SWITZERLAND - September 4, 2026 - VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA” or the “Company”), a leading developer of next-generation antibody-based cancer therapies, today announ…
Read attachment ↗veraxabiotechag_ex99-1.htm · 6-K · 2026-08-24
Exhibit 99.1 Press Release VERAXA Biotech and Secarna Pharmaceuticals Achieve Research Milestone in Antibody Oligonucleotide Conjugate (AOC) Alliance Successful in vitro proof-of-concept study demonstrates the potential to create novel antibody-oligonucleotide conjugates (AOCs) by combining both parties’ technologies and expertise ZURICH, SWITZERLAND, and MARTINSRIED/MUNICH, GERMANY - August 24, 2026 - VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in the design and developm…
Read attachment ↗veraxabiotech_ex107.htm · F-1 · 2026-07-31
Veraxa Biotech Holding AG Exhibit 107 Calculation of Filing Fee Table Form F-1 (Form Type)N/A Veraxa Biotech AG (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Security Class Title Fee Amount Proposed Maximum Fee Rate A…
Read attachment ↗veraxabiotech_ex107.htm · F-1 · 2026-07-31
Veraxa Biotech Holding AG Exhibit 107 Calculation of Filing Fee Table Form F-1 (Form Type)N/A Veraxa Biotech AG (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Security Class Title Fee Amount Proposed Maximum Fee Rate Amount of Type …
Read attachment ↗veraxabiotechag_ex99-1.htm · 6-K · 2026-07-31
Exhibit 99.1 Press Release VERAXA Biotech Strengthens Patent Portfolio to Protect Core Technology Platforms and Product Candidates First BiTAC ® -related patent applications filed in H1 2026 including patents covering composition of matter and proprietary payload platform, with additional patents secured in contributing technology areas including click chemistry and conjugation technology. ZURICH, SWITZERLAND - July 29, 2026 -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader i…
Read attachment ↗